| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
 |
|
Site Navigation
| ALS News & Research For postings of news or research links and articles related to ALS |
advertisement
| Reply |
|
|
Thread Tools | Display Modes |
|
|
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
03-20-2017, 11:02 AM
|
#1 | |||
|
||||
|
Grand Magnate
|
AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)
AB Science announces positive top-line results of final analysis from study AB1 15 of masitinib in amyotrophic lateral sclerosis (ALS) Paris Stock Exchange:AB |
|||
|
 Reply With Quote
|
| Reply |
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| NeuroDerm Announces Positive Topline Results of Phase II Trials | Parkinson's Disease | |||
| Civitas Therapeutics Announces Positive Phase 2b Results for CVT-301, Inhaled Levodop | Parkinson's Disease | |||
| Hisamitsu announces positive Phase II results for Parkinson’s disease drug | Parkinson's Disease | |||
| NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Pa | Parkinson's Disease | |||
| Ceregene announces positive phase 1 results ... | Parkinson's Disease | |||
AB Science announces positive top-line results of final analysis from study AB10015
Linear Mode
